FDA Approves MACITENTAN — Novugen Pharma (USA) LLC

# FDA Approves Generic MACITENTAN from Novugen Pharma The FDA has approved Novugen Pharma's generic version of MACITENTAN, an endothelin receptor antagonist used to treat pulmonary arterial hypertension, potentially opening the market to lower-cost alternatives and increasing competition in the PAH treatment space. The approval could significantly impact pricing dynamics and market share for branded MACITENTAN while expanding patient access to this important therapeutic option.